PHAXIAM Therapeutics Facing Potential Liquidation Amid Court Hearing Postponement

On June 4, 2025, PHAXIAM Therapeutics announced a postponement in the offer review hearing initially scheduled by the Lyon Commercial Court. The new date for the hearing is set for June 11, 2025. This hearing is pivotal as the court will decide on the conversion of PHAXIAM’s judicial reorganization into liquidation, regardless of the bid outcome.

PHAXIAM plans to request the delisting of its shares from Euronext, reflecting the gravity of its financial challenges. The company's indebtedness is significant, and even the acceptance of a potential bid may not offer relief to shareholders. PHAXIAM has been focusing on developing treatments targeting resistant bacterial infections using phages.

This development casts uncertainty on the future of the company, potentially affecting its investors and stakeholders significantly.